Genscript Biotech Corporation (GNNSF)
OTCMKTS · Delayed Price · Currency is USD
2.150
0.00 (0.00%)
Oct 24, 2025, 4:00 PM EDT
Genscript Biotech Revenue
Genscript Biotech had revenue of $518.77M in the half year ending June 30, 2025, with 32.57% growth. This brings the company's revenue in the last twelve months to $828.10M, up 63.20% year-over-year. In the year 2024, Genscript Biotech had annual revenue of $594.49M with 6.07% growth.
Revenue (ttm)
828.10M
Revenue Growth
+63.20%
P/S Ratio
5.51
Revenue / Employee
143.54K
Employees
5,568
Market Cap
4.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 594.49M | 34.01M | 6.07% |
| Dec 31, 2023 | 560.48M | -65.22M | -10.42% |
| Dec 31, 2022 | 625.70M | 135.60M | 27.67% |
| Dec 31, 2021 | 490.10M | 99.25M | 25.39% |
| Dec 31, 2020 | 390.85M | 117.49M | 42.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Genscript Biotech News
- 2 months ago - Genscript Biotech Corporation (GNNSF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation - PRNewsWire
- 3 months ago - GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader - PRNewsWire
- 4 months ago - China’s drug innovators bank on AI to hasten discovery to commercial success - South China Morning Post
- 7 months ago - Genscript Biotech Corporation 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 8 months ago - Genscript Biotech Corp (GNNSF) (FY 2024) Earnings Call Highlights: Record Profits and Strategic ... - GuruFocus
- 8 months ago - GenScript Biotech Corporation Reports FY 2024 Results - PRNewsWire
- 1 year ago - The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development - PRNewsWire